All-trans retinoic acid compromises desmosome expression in human epidermis.
An undesirable side-effect of retinoid treatment is skin fragility. As desmosomes are important in maintaining the cohesion of epidermal keratinocytes, we investigated whether all-trans-retinoic acid (RA) compromises desmosome expression in human epidermis, thereby predisposing skin to fragility. Solutions containing 0.025% RA, 5% sodium dodecyl sulphate (SDS) as an irritant control, or vehicle alone were applied to three sites on the buttocks of normal volunteers (n = 9). Treated sites were occluded for 4 days, and biopsies taken under local anaesthesia. Cryostat sections were stained with a panel of antibodies to desmosomal proteins and visualized by immunofluorescence microscopy. Stained sections were randomized and assessed for intensity of staining. The epidermal thickness of each treated site was quantified by image analysis. Western blots of epidermal desmocollins were quantified by densitometry. RA and SDS treatments significantly, but equivalently, increased epidermal thickness compared with vehicle. Immunohistochemically, both RA and SDS were shown to reduce epidermal staining for desmoplakin, desmoglein 1, plakophilin 1 and desmocollin 3 equally compared with vehicle-treated skin (P < 0.001). RA produced a greater reduction in desmocollin 1 staining compared with SDS (P < 0.001). Similar reductions in desmocollins were found by Western blot analysis. Reduced desmocollin expression may indicate compromised desmosomal adhesion, leading to the skin fragility that results from retinoid treatment.
Humphries
J D
JD
Section of Dermatology, Department of Medicine, University of Manchester, Hope Hospital, Salford M6 8HD, U.K.
Parry
E J
EJ
Watson
R E
RE
Garrod
D R
DR
Griffiths
C E
CE
D000328:Adult; D015153:Blotting, Western / Q000379:methods; D003896:Desmosomes / Q000187:drug effects*; D004890:Erythema / Q000209:etiology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007509:Irritants; D007641:Keratolytic Agents / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000139:chemically induced*; D012967:Sodium Dodecyl Sulfate; D013501:Surface-Active Agents; D014212:Tretinoin / Q000009:adverse effects*
D007509:Irritants; D007641:Keratolytic Agents; D013501:Surface-Active Agents; D012967:Sodium Dodecyl Sulfate; D014212:Tretinoin